An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | July 2010 |
| End Date: | September 2012 |
A Multi-centre Observational Study to Describe Usage and Dosification Patterns of RoActemra (Tocilizumab) Treatment in Rheumatoid Arthritis (RA) Patients in the Routine Clinical Practice. ACT-LIFE Study
This observational study will evaluate the dosage patterns, safety and efficacy of
RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe
rheumatoid arthritis who have not responded or are intolerant to at least one
disease-modifying antirheumatic drug (DMARD) or TNF inhibitor. Data will be collected from
each patients for 12 months.
RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe
rheumatoid arthritis who have not responded or are intolerant to at least one
disease-modifying antirheumatic drug (DMARD) or TNF inhibitor. Data will be collected from
each patients for 12 months.
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Moderate to severe rheumatoid arthritis (RA) of at least 6 months duration
- Non-responder or intolerant to at least one DMARD or TNF inhibitor treatment
- Initiated on treatment with RoActemra according to Summary of Product Characteristics
(SPC) indications
Exclusion Criteria:
- History of autoimmune disease or of any joint inflammatory disease other than RA
- Pregnant or lactating women
- Patients who have started RoActemra treatment in a clinical trial or for
compassionate use
- Treatment with any investigational drug in the previous 4 weeks (or at least 5 times
the half-life of the drug)
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials